Related Experiment Video
Updated: Jul 20, 2025
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.5K
Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction
Rasha Kaddoura1, Ashfaq Patel2
1Pharmacy Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Current Problems in Cardiology
|August 6, 2023
Summary
Beta blockers show conflicting efficacy in treating heart failure with preserved ejection fraction (HFpEF). This review examines existing studies to clarify their role in HFpEF management, particularly for elderly, female, and obese patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure with preserved ejection fraction (HFpEF) is a complex condition predominantly affecting elderly, female, and obese individuals.
- Current classifications of HFpEF utilize varying left ventricular ejection fraction cut-offs, with ≥50% being a common threshold.
- The therapeutic role of beta-blockers in HFpEF remains controversial, with inconsistent evidence regarding their effectiveness.
Purpose of the Study:
- To systematically review and analyze published studies investigating the efficacy of beta-blocker therapy in patients diagnosed with HFpEF.
- To synthesize current evidence to provide a clearer understanding of beta-blocker utility in HFpEF management.
Main Methods:
- Comprehensive literature search of relevant databases for studies on beta-blockers and HFpEF.
- Critical appraisal of study methodologies and reported outcomes related to beta-blocker treatment in HFpEF patients.
Main Results:
- Evidence regarding beta-blocker efficacy in HFpEF patients is characterized by conflicting findings across studies.
- Reported efficacy of beta-blockers varies significantly, necessitating further investigation into their specific role.
Conclusions:
- The current body of evidence does not definitively establish the benefit of beta-blockers for all HFpEF patients.
- Further research is required to elucidate the precise role and optimal use of beta-blockers in the heterogeneous HFpEF population.
More Related Videos
07:09A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
1.9K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.5K
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:26Heart Failure Drugs: Inotropic Agents
622
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
622
01:30Heart Failure IV: Classification and Diagnostic Evaluation
19
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
19